Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
HOME > TOP STORIES
TOP STORIES
-
ORGANIZATION Mobile Pharmacy Van Set in Motion as Kumamoto Downpour Hits Local Stores, Some Wholesalers
July 8, 2020
-
ORGANIZATION Wholesaler Group Makes Emergency Plea against Off-Year Drug Price Survey
July 7, 2020
-
BUSINESS Ono to Fight Prof. Honjo’s Lawsuit over Opdivo Royalties
July 7, 2020
-
REGULATORY Japan Govt Likely to Stick to 2020 Off-Year Drug Re-Pricing Plan in Honebuto Paper
July 6, 2020
-
BUSINESS Maviret Shrivels, but AbbVie Japan in “Growth Mode” with Oncology, Immunology Drivers: Chief
July 3, 2020
-
ORGANIZATION COVID-19 Having “Serious Impact” on New Drug Development; JPMA Calls for Strong Systems for Emergencies
July 2, 2020
-
BUSINESS 26 Japan Drug Makers Log 4% Fall in Workforce as Downtrend Continues Unabated: FY2019 Securities Reports
July 1, 2020
-
BUSINESS AnGes Launches Clinical Trial for Coronavirus DNA Vaccine
July 1, 2020
-
REGULATORY Japan Approves Entresto, 4 Other Novartis Meds, Rybelsus, 1st Humira Biosimilar and More
June 30, 2020
-
BUSINESS Novo Japan Chief Sees 100 Billion Yen Target Achievable on Ozempic, Rybelsus
June 30, 2020
-
BUSINESS Pfizer Japan Boosting Biosimilar Sales Structure with Dedicated Unit, Ups Its Quality Pitch
June 29, 2020
-
BUSINESS AstraZeneca in Talks with Daiichi Sankyo, Meiji Group on COVID-19 Vaccine Supplies in Japan
June 29, 2020
-
REGULATORY Japan OK for MSD’s 9-Valent HPV Vaccine Could Be Delayed after Deluge of Comments Hit Proposed Rule Changes
June 26, 2020
-
BUSINESS Sosei, AbbVie Link Arms for Inflammatory and Autoimmune Disease Drugs
June 26, 2020
-
BUSINESS Takeda’s CEO Pay Tops 2 Billion Yen in FY2019; Old Guard Pitch to Send in External Director Rejected
June 25, 2020
-
BUSINESS 7 Authorized Generics in June Listing Target Combined 260 Billion Yen Market; Simultaneous Launches Catching On
June 24, 2020
-
BUSINESS Rohto to Launch Stem Cell Clinical Trial for COVID-19 in August, Eyes Conditional OK
June 24, 2020
-
BUSINESS Ayumi Chief Says Contender Debut Will Add Vigor to Enbrel Biosimilar Space, Sees Govt Fee Incentive as Booster
June 23, 2020
-
REGULATORY MHLW to Hasten Electronic Scrip Rollout to Summer 2022: Health Minister
June 23, 2020
-
REGULATORY Sakigake Status Awarded to GSK’s Next-Gen I/O Therapy, 2 More Drugs; System Possibly Subject to Review Next Time
June 22, 2020
ページ
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…